Southwest Virginia Wildlife Center rehabilitating bobcat kitten
It was picked up in Floyd on May 21, after it was discovered near its mother, who had been hit and killed by a car.
'Luckily, he did get away from that incident and he has no major injuries,' said Southwest Virginia Wildlife Center volunteer coordinator Catherine McGrath. 'The vets have looked over him and he's in fantastic health. All he's going to need as we raise him are a couple vaccinations.'
The center is working to rehabilitate him and is targeting a spring 2026 release date.
'He's going to be here for a very long time because that's how long it's going to take him to essentially grow up and be large enough to survive while in the wild,' said McGrath.
Southwest Virginia Wildlife Center receives first-ever rare Eastern Spotted Skunk
He has to be fed a specialized formula every two-to-three hours, and staff have to wear full protective gear when interacting with him because of how susceptible big cats are to COVID-19.
Staff members are also working hard to avoid having the animal bond with them, a process they say would complicate things upon its release back into the wild.
'Because the bobcat is going to take about a half a year to ween, that's a lot of interaction with people and not a lot of interaction with another of his own species,' said McGrath. 'So, what we want to do is mitigate him associating us with food and care.'
She also said the Center is actively looking for another bobcat kitten in need of rehabilitation so that the two can grow up as a pair.
'You never want to raise any sort of baby alone,' said McGrath. 'You want to raise them in pairs because that reduces the risk of habituation.'
The whole rehab process is an expensive one, and the Southwest Virginia Wildlife Center says it is looking for some assistance in the form of donations.
'By the time we're getting him ready for release, he's eating four times more than the average house cat,' said McGrath. 'And when you add that up to a year of that sort of care, that is thousands of dollars of specialized food for him.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
12 minutes ago
- Business Wire
SelectQuote, Inc. Reports Fourth Quarter of Fiscal Year 2025 Results
OVERLAND PARK, Kan.--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the fourth quarter of fiscal year 2025 of $345.1 million compared to consolidated revenue for the fourth quarter of fiscal year 2024 of $307.2 million. Consolidated net income for the fourth quarter of fiscal year 2025 was $12.9 million compared to consolidated net loss for the fourth quarter of fiscal year 2024 of $31.0 million. Finally, consolidated Adjusted EBITDA* for the fourth quarter of fiscal year 2025 was $2.7 million compared to consolidated Adjusted EBITDA* for the fourth quarter of fiscal year 2024 of $14.4 million. Tim Danker, SelectQuote Chief Executive Officer, commented 'The strength of our holistic healthcare services model was broadly exhibited in fiscal 2025, and we firmly believe the years ahead will increasingly drive substantial value for each of our stakeholders. Policyholders and patients will continue to benefit from our information advantage through tailored advice and healthcare solutions, which ultimately result in better health outcomes. Our insurance and healthcare service partners benefit from better treatment fit and adherence, which eliminates waste and serves to ease the historical trend of rising healthcare costs for Americans. Additionally, we believe our shareholders will benefit as SelectQuote's diverse breadth of revenues drive increasing cash flow, which will accelerate and compound with new growth initiatives in the future.' Mr. Danker continued, 'We are proud to have delivered financial results well in excess of our initial expectations for the 3rd consecutive year. Over that period, our Adjusted EBITDA results have outperformed our forecasts by more than 20% each year. Our leadership and workforce have accomplished these results through significant change in Medicare Advantage in each year. We credit the talent and hard work of our people and are exceedingly proud of the track record SelectQuote has built as an agile, innovative and reliable source of value for Americans seeking healthcare that best fits their needs.' * See 'Non-GAAP Financial Measures' below. Segment Results We currently have three reportable segments: 1) Senior, 2) Healthcare Services and 3) Life. The performance measures of the segments include total revenue and Adjusted EBITDA.* Costs of commissions and other services revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount. Adjusted EBITDA is our segment profit measure to evaluate the operating performance of our business. We define Adjusted EBITDA as income (loss) before income tax expense (benefit) plus: (i) interest expense, net; (ii) depreciation and amortization; (iii) share-based compensation; (iv) goodwill, long-lived asset, and intangible assets impairments; (v) transaction costs; (vi) loss on disposal of property, equipment and software, net; (vii) other non-recurring expenses and income; (viii) changes in fair value of warrant liabilities. Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by revenue. Senior Financial Results The following table provides the financial results for the Senior segment for the periods presented: Operating Metrics Submitted Policies Submitted policies are counted when an individual completes an application with our licensed agent and provides authorization to the agent to submit the application to the insurance carrier partner. The applicant may have additional actions to take before the application will be reviewed by the insurance carrier. The following table shows the number of submitted policies for the periods presented: * See 'Non-GAAP Financial Measures' below. Approved Policies Approved policies represents the number of submitted policies that were approved by our insurance carrier partners for the identified product during the indicated period. Not all approved policies will go in force. The following table shows the number of approved policies for the periods presented: Lifetime Value of Commissions per Approved Policy Lifetime value of commissions per approved policy represents commissions estimated to be collected over the estimated life of an approved policy based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints. The lifetime value of commissions per approved policy is equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions. The following table shows the lifetime value of commissions per approved policy for the periods presented: Healthcare Services Financial Results The following table provides the financial results for the Healthcare Services segment for the periods presented: Three Months Ended June 30, Year Ended June 30, (in thousands) 2025 2024 % Change 2025 2024 % Change Revenue $ 214,028 $ 145,223 47 % $ 742,705 $ 478,508 55 % Adjusted EBITDA* 11,853 909 1,204 % 25,387 7,821 225 % Adjusted EBITDA Margin* 6 % 1 % 3 % 2 % Expand Operating Metrics Members The total number of SelectRx members represents the amount of active customers to which an order has been shipped and the prescriptions per day represents the total average prescriptions shipped per business day. These two metrics are the primary drivers of revenue for Healthcare Services. * See 'Non-GAAP Financial Measures' below. The following table shows the total number of SelectRx members as of the periods presented: The total number of SelectRx members increased by 31% as of June 30, 2025, compared to June 30, 2024, due to our strategy to grow SelectRx membership. The following table shows the average prescriptions shipped per day for the periods presented: Combined Senior and Healthcare Services - Consumer Per Unit Economics Combined Senior and Healthcare Services consumer per unit economics represents total MA and MS commissions; other product commissions; other revenues, including revenues from Healthcare Services; and operating expenses associated with Senior and Healthcare Services, each shown per number of approved MA and MS policies over a given time period. Management assesses the business on a per-unit basis to help ensure that the revenue opportunity associated with a successful policy sale is attractive relative to the marketing acquisition cost. Because not all acquired leads result in a successful policy sale, all per-policy metrics are based on approved policies, which is the measure that triggers revenue recognition. The MA and MS commission per MA/MS policy represents the LTV for policies sold in the period. Other commission per MA/MS policy represents the LTV for other products sold in the period, including DVH prescription drug plan, and other products, which management views as additional commission revenue on our agents' core function of MA/MS policy sales. Pharmacy revenue per MA/MS policy represents revenue from SelectRx, and other revenue per MA/MS policy represents revenue from Population Health, production bonuses, marketing development funds, lead generation revenue, and adjustments from the Company's reassessment of its cohorts' transaction prices. Total operating expenses per MA/MS policy represents all of the operating expenses within Senior and Healthcare Services. The revenue to customer acquisition cost ('CAC') multiple represents total revenue as a multiple of total marketing acquisition cost, which represents the direct costs of acquiring leads. These costs are included in marketing and advertising expense within the total operating expenses per MA/MS policy. The following table shows combined Senior and Healthcare Services consumer per unit economics for the periods presented. Based on the seasonality of Senior and the fluctuations between quarters, we believe that the most relevant view of per unit economics is on a rolling 12-month basis. All per MA/MS policy metrics below are based on the sum of approved MA/MS policies, as both products have similar commission profiles. Total revenue per MA/MS policy increased 22% for the twelve months ended June 30, 2025, compared to the twelve months ended June 30, 2024, primarily due to the increase in pharmacy revenue. Total operating expenses per MA/MS policy increased 27% for the twelve months ended June 30, 2025, compared to the twelve months ended June 30, 2024, driven by an increase in cost of goods sold-pharmacy revenue for Healthcare Services due to the growth of the business. Life Financial Results The following table provides the financial results for the Life segment for the periods presented: Operating Metrics Life premium represents the total premium value for all policies that were approved by the relevant insurance carrier partner and for which the policy document was sent to the policyholder and payment information was received by the relevant insurance carrier partner during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Life segment. The following table shows term and final expense premiums for the periods presented: * See 'Non-GAAP Financial Measures' below. Earnings Conference Call SelectQuote, Inc. will host a conference call with the investment community on August 21, 2025, beginning at 8:30 a.m. ET. To register for this conference call, please use this link: After registering, a confirmation will be sent via email, including dial-in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call we suggest registering at least 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website Non-GAAP Financial Measures This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA, which is a non-GAAP financial measure. This non-GAAP financial measure is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to any similarly titled measure presented by other companies. We define Adjusted EBITDA as net income (loss) before income tax expense (benefit), plus interest expense, depreciation and amortization, changes in fair value of warrant liabilities, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure is net income (loss) before income tax expense (benefit). We monitor and have presented in this release Adjusted EBITDA because it is a key measure used by our management and Board of Directors to understand and evaluate our operating performance, establish budgets, and develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance. Reconciliations of net income (loss) before income tax expense (benefit) to Adjusted EBITDA are presented below beginning on page 12. The Company is unable to provide a quantitative reconciliation of forward-looking Adjusted EBITDA to its most directly comparable GAAP measure without unreasonable effort because it is not possible to predict certain information included in the calculation of such GAAP measure, including the fair value of outstanding warrants to purchase shares of the Company's common stock. The unavailable information could have a significant impact on the Company's GAAP financial results. Forward Looking Statements This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as 'may,' 'should,' 'could,' 'predict,' 'potential,' 'believe,' 'will likely result,' 'expect,' 'continue,' 'will,' 'anticipate,' 'seek,' 'estimate,' 'intend,' 'plan,' 'projection,' 'would' and 'outlook,' or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts and are based on current expectations, estimates and projections about our industry, management's beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost-effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation and tariffs; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; existing or potential litigation and other legal proceedings or inquiries, including the Department of Justice action alleging violations of the federal False Claims Act; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers' approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, contractual reimbursement rates, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled 'Risk Factors' in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025 (the 'Annual Report') and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.. About SelectQuote: Founded in 1985, SelectQuote (NYSE: SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote's success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care. With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select which proactively connects consumers with a wide breadth of healthcare services supporting their needs. Source: SelectQuote, Inc. June 30, 2024 ASSETS CURRENT ASSETS: Cash, cash equivalents, and restricted cash $ 35,733 $ 42,690 Accounts receivable, net of allowances of $11.8 million and $8.2 million, respectively 151,388 150,035 Commissions receivable-current 132,077 119,871 Other current assets 21,844 20,327 Total current assets 341,042 332,923 COMMISSIONS RECEIVABLE—Net 818,751 761,446 PROPERTY AND EQUIPMENT—Net 14,577 18,973 SOFTWARE—Net 15,060 13,978 OPERATING LEASE RIGHT-OF-USE ASSETS 24,635 23,437 INTANGIBLE ASSETS—Net 1,973 10,194 GOODWILL 29,438 29,438 OTHER ASSETS 3,880 3,519 TOTAL ASSETS $ 1,249,356 $ 1,193,908 LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 59,205 $ 36,587 Accrued expenses 13,856 16,904 Accrued compensation and benefits 58,788 57,594 Operating lease liabilities—current 4,820 4,709 Current portion of long-term debt 68,523 45,854 Contract liabilities 698 8,066 Other current liabilities 7,020 4,873 Total current liabilities 212,910 174,587 LONG-TERM DEBT, NET—less current portion 316,589 637,480 DEFERRED INCOME TAXES 37,872 37,478 OPERATING LEASE LIABILITIES 25,982 25,685 OTHER LIABILITIES 80,485 1,877 Total liabilities 673,838 877,107 COMMITMENTS AND CONTINGENCIES PREFERRED STOCK: Senior Non-Convertible Preferred Stock, $0.01 par value, 350,000 shares and no shares issued and outstanding as of June 30, 2025 and June 30, 2024, respectively, current liquidation preference of $367.1 million and $0.0 million as of June 30, 2025 and June 30, 2024, respectively 224,374 — SHAREHOLDERS' EQUITY: Common stock, $0.01 par value 1,728 1,694 Additional paid-in capital 571,605 580,764 Accumulated deficit (222,189 ) (269,769 ) Accumulated other comprehensive income — 4,112 Total shareholders' equity 351,144 316,801 TOTAL LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS' EQUITY $ 1,249,356 $ 1,193,908 Expand SELECTQUOTE, INC. AND SUBSIDIARIES (Unaudited) (In thousands) Three Months Ended June 30, Year Ended June 30, 2025 2024 2025 2024 REVENUE: Commissions and other services $ 134,503 $ 165,656 $ 797,841 $ 856,923 Pharmacy 210,599 141,552 728,753 464,853 Total revenue 345,102 307,208 1,526,594 1,321,776 OPERATING COSTS AND EXPENSES: Cost of commissions and other services revenue 58,844 64,548 305,127 318,798 Cost of goods sold—pharmacy revenue 182,312 120,644 630,340 405,004 Marketing and advertising 65,283 70,181 319,505 358,858 Selling, general, and administrative 9,594 43,993 164,442 141,042 Technical development 41,591 9,233 38,681 33,524 Total operating costs and expenses 357,624 308,599 1,458,095 1,257,226 INCOME (LOSS) FROM OPERATIONS (12,522 ) (1,391 ) 68,499 64,550 INTEREST EXPENSE, NET (12,226 ) (23,409 ) (79,385 ) (93,551 ) CHANGE IN FAIR VALUE OF WARRANTS 34,181 — 59,525 — OTHER EXPENSE, NET (58 ) (15 ) (128 ) (65 ) INCOME (LOSS) BEFORE INCOME TAX EXPENSE (BENEFIT) 9,375 (24,815 ) 48,511 (29,066 ) INCOME TAX EXPENSE (BENEFIT) (3,493 ) 6,202 931 5,059 NET INCOME (LOSS) $ 12,868 $ (31,017 ) $ 47,580 $ (34,125 ) Senior Non-Convertible Preferred Stock accumulated dividends and accretion $ (16,762 ) $ — $ (22,548 ) $ — NET INCOME (LOSS) ATTRIBUTABLE TO COMMON SHAREHOLDERS PER SHARE: Basic $ (0.02 ) $ (0.18 ) $ 0.14 $ (0.20 ) Diluted $ (0.02 ) $ (0.18 ) $ 0.01 $ (0.20 ) WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS: Basic 184,201 169,204 176,148 168,519 OTHER COMPREHENSIVE LOSS NET OF TAX: Change in cash flow hedge — (2,364 ) (4,112 ) (9,567 ) OTHER COMPREHENSIVE LOSS — (2,364 ) (4,112 ) (9,567 ) COMPREHENSIVE INCOME (LOSS) $ 12,868 $ (33,381 ) $ 43,468 $ (43,692 ) Expand SELECTQUOTE, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (In thousands) Three Months Ended June 30, Year Ended June 30, 2025 2024 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES: Net income (loss) $ 12,868 $ (31,017 ) $ 47,580 $ (34,125 ) Adjustments to reconcile net income (loss) to net cash, cash equivalents, and restricted cash used in operating activities: Depreciation and amortization 4,876 6,407 20,460 24,998 Loss on disposal of property, equipment, and software 80 523 240 536 Impairment of long-lived assets 4,209 — 4,209 — Share-based compensation expense 4,852 3,304 18,357 13,816 Deferred income taxes (2,576 ) 3,314 1,849 1,163 Amortization of debt issuance costs and debt discount 1,367 1,279 5,247 6,142 Write-off of debt issuance costs — — 93 293 Accrued interest payable in kind 713 5,254 14,013 19,577 Change in fair value of warrants (34,181 ) — (59,525 ) — Non-cash lease expense 1,072 404 3,922 2,349 Bad debt expense — — 4,203 — Changes in operating assets and liabilities: Accounts receivable, net 33,491 103,722 (5,555 ) 5,203 Commissions receivable (35,745 ) (48,194 ) (69,510 ) (40,819 ) Other assets (5,938 ) 653 (6,282 ) (1,967 ) Accounts payable and accrued expenses (21,936 ) (28,726 ) 19,226 7,347 Operating lease liabilities (1,137 ) (1,095 ) (4,711 ) (4,897 ) Other liabilities 503 4,167 (5,482 ) 15,620 Net cash provided by (used in) operating activities (37,482 ) 19,995 (11,666 ) 15,236 CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property and equipment (501 ) (268 ) (2,191 ) (3,382 ) Proceeds from sales of property and equipment — — — 253 Purchases of software and capitalized software development costs (2,610 ) (2,219 ) (9,123 ) (8,284 ) Acquisition of business — (3,433 ) — (3,433 ) Net cash used in investing activities (3,111 ) (5,920 ) (11,314 ) (14,846 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from revolving line of credit — — 166,900 — Payments on revolving line of credit — — (166,900 ) — Payments on Term Loans (3,573 ) (8,471 ) (388,216 ) (38,883 ) Proceeds from ABS Notes — — 99,095 — Payments on ABS Notes (4,855 ) — (16,577 ) — Payments on other debt (108 ) (37 ) (312 ) (149 ) Proceeds from common stock options exercised and employee stock purchase plan (14 ) 74 98 81 Proceeds from issuance of Senior Non-Convertible Preferred Stock — — 337,855 — Senior Non-Convertible Preferred Stock issuance costs — — (7,076 ) — Payments of tax withholdings related to net share settlement of equity awards (13 ) (1 ) (5,032 ) (374 ) Payments of debt issuance costs — (758 ) (2,479 ) (1,531 ) Net cash provided by (used in) financing activities (8,563 ) (9,193 ) 17,356 (40,856 ) (49,156 ) 4,882 (5,624 ) (40,466 ) CASH, CASH EQUIVALENTS AND RESTRICTED CASH —Beginning of period 86,222 37,808 42,690 83,156 CASH, CASH EQUIVALENTS AND RESTRICTED CASH —End of period $ 37,066 $ 42,690 $ 37,066 $ 42,690 Expand Three Months Ended June 30, 2025 (in thousands) Senior Healthcare Services Life Total Less: Cost of commissions and other services revenue (32,391 ) (5,536 ) (18,020 ) Cost of goods sold - pharmacy revenue — (180,988 ) — Marketing expense (41,752 ) (1,950 ) (22,813 ) Technical development — (495 ) — Selling, general, and administrative (599 ) (13,206 ) (229 ) Adjusted Segment EBITDA 7,722 11,853 6,922 26,497 Reconciliation of total segment Adjusted EBITDA All other Adjusted EBITDA 950 Corporate (24,753 ) Share-based compensation expense (4,852 ) Transaction costs (1,257 ) Depreciation and amortization (4,876 ) Loss on disposal of property, equipment, and software, net (80 ) Impairment of long-lived assets (4,209 ) Change in fair value of warrants 34,181 Interest expense, net (12,226 ) Income before income tax expense (benefit) $ 9,375 Expand Three Months Ended June 30, 2024 (in thousands) Senior Healthcare Services Life Total Total revenue from reportable segments $ 114,143 $ 145,223 $ 42,074 $ 301,440 Less: Cost of commissions and other services revenue (37,534 ) (5,025 ) (15,287 ) Cost of goods sold - pharmacy revenue — (119,520 ) — Marketing expense (48,138 ) (1,700 ) (19,279 ) Technical development — (835 ) — Selling, general, and administrative (599 ) (17,234 ) (291 ) Adjusted Segment EBITDA 27,872 909 7,217 35,998 Reconciliation of total segment Adjusted EBITDA All other Adjusted EBITDA 2,474 Corporate (24,115 ) Share-based compensation expense (3,304 ) Transaction costs (5,529 ) Depreciation and amortization (6,407 ) Loss on disposal of property, equipment, and software, net (523 ) Interest expense, net (23,409 ) Loss before income tax expense (benefit) $ (24,815 ) Expand SELECTQUOTE, INC. AND SUBSIDIARIES Adjusted EBITDA to Income (Loss) before income tax expense (benefit) Reconciliation (Unaudited) Year Ended June 30, 2025 Total revenue from reportable segments $ 600,393 $ 742,705 $ 172,978 $ 1,516,076 Less: Cost of commissions and other services revenue (201,933 ) (25,163 ) (65,047 ) Cost of goods sold - pharmacy revenue — (625,389 ) — Marketing expense (234,335 ) (8,038 ) (80,269 ) Technical development — (2,187 ) — Selling, general, and administrative (2,454 ) (56,541 ) (993 ) Adjusted Segment EBITDA 161,671 25,387 26,669 213,727 Reconciliation of total segment Adjusted EBITDA All other Adjusted EBITDA 10,597 Corporate (98,070 ) Share-based compensation expense (18,357 ) Transaction costs (14,617 ) Depreciation and amortization (20,460 ) Loss on disposal of property, equipment, and software, net (240 ) Impairment of long-lived assets (4,209 ) Change in fair value of warrants 59,525 Interest expense, net (79,385 ) Income before income tax expense (benefit) $ 48,511 Expand Year Ended June 30, 2024 (in thousands) Senior Healthcare Services Life Total Total revenue from reportable segments $ 655,849 $ 478,508 $ 157,930 $ 1,292,287 Less: Cost of commissions and other services revenue (216,348 ) (17,438 ) (60,017 ) Cost of goods sold - pharmacy revenue — (400,821 ) — Marketing expense (269,867 ) (6,260 ) (76,513 ) Technical development — (915 ) — Selling, general, and administrative (2,890 ) (45,253 ) (1,236 ) Adjusted Segment EBITDA 166,744 7,821 20,164 194,729 Reconciliation of total segment Adjusted EBITDA All other Adjusted EBITDA 14,127 Corporate (91,863 ) Share-based compensation expense (13,816 ) Transaction costs (13,158 ) Depreciation and amortization (24,998 ) Loss on disposal of property, equipment, and software, net (536 ) Interest expense, net (93,551 ) Loss before income tax expense (benefit) $ (29,066 ) Expand
Business Wire
41 minutes ago
- Business Wire
Enanta Pharmaceuticals to Participate in September Investor Conferences
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in three investor conferences in September: H.C. Wainwright 27 th Annual Global Investment Conference: Fireside Chat on Tuesday, September 9, 2025 at 2:00 p.m. ET Baird 2025 Global Healthcare Conference: Fireside Chat on Wednesday, September 10, 2025 at 12:15 p.m. ET A live webcast of each event will be accessible by visiting the 'Events and Presentations' section on the 'Investors' page of Enanta's website at A replay of the webcasts will be available following the presentation and will be archived for at least 30 days. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit for more information.
Yahoo
an hour ago
- Yahoo
H.C. Wainwright Reiterates a Buy on CG Oncology (CGON), Keeps the PT
CG Oncology, Inc. (NASDAQ:CGON) is one of the Best Small-Cap Growth Stocks to Buy Right Now. On August 11, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on CG Oncology, Inc. (NASDAQ:CGON) with a price target of $75. The analyst noted that the company is making good progress with its drug Cretostimogene for treating BCG-unresponsive high-risk non-muscle invasive bladder cancer. Data from the ongoing studies is expected by the end of 2025, which Maldonado believes will be a key milestone. In addition, the BOND-003 study shows a strong median duration of response, which is supported by stable immune system activity, indicating long-term control of the disease. A biotechnologist in a lab setting, examining a sample of liquid for research and development. Maldonado highlighted that CG Oncology, Inc. (NASDAQ:CGON) is improving its drug administration and stability, which makes it easier for urologists to adopt the treatment. Moreover, the analyst sees faster patient enrollment in trials and growing market awareness as positive signs for the company. CG Oncology, Inc. (NASDAQ:CGON) is a biotechnology company that develops treatments for bladder cancer, focusing on bladder-sparing therapies. While we acknowledge the potential of CGON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
